AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2025
Feb 6, 2025
30591_dirs_2025-02-06_533afad8-791b-46b2-ad64-edcbb95e3f89.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2025-02-04
Reporting Person: Monia Brett P (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-04 | Common Stock | S | 38843 | $31.6521 | Disposed | 180683 | Direct |
Footnotes
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.555 to $31.755 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.